Tissue Regenix Group plc (AIM:TRX)

Tissue Regenix Group Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-1.37	-0.71	-1.71	-2.7	-4.79	-12.47
Depreciation & Amortization	1.05	1.05	0.98	1.14	1.09	1.05
Other Amortization	0.04	0.04	0.16	0.09	0.08	0.08
Asset Writedown & Restructuring Costs	-	-	-	-	-	7.87
Stock-Based Compensation	0.4	0.36	0.34	0.25	0.11	-0.04
Other Operating Activities	0.89	1.22	1.51	0.55	1.01	1.6
Change in Accounts Receivable	0.17	-0.93	1.07	-0.7	-0.51	-0.26
Change in Inventory	-4.08	-3.84	0.52	-1.16	-0.12	-4.12
Change in Accounts Payable	2.44	1.18	-1.84	1.25	0.16	0.22
Operating Cash Flow	-0.46	-1.64	1.04	-1.29	-2.98	-6.06
Capital Expenditures	-3.09	-3.3	-0.41	-0.38	-1.55	-1.57
Sale (Purchase) of Intangibles	-1	-0.77	-0.45	-0.71	-0.5	-0.29
Other Investing Activities	0.01	0.01	0.03	0.01	0	0
Investing Cash Flow	-4.09	-4.06	-0.84	-1.08	-2.04	-1.86
Long-Term Debt Issued	-	4.27	-	1.71	0.6	0.72
Long-Term Debt Repaid	-	-0.19	-0.38	-0.07	-0.1	-
Net Debt Issued (Repaid)	3.54	4.08	-0.38	1.64	0.5	0.72
Issuance of Common Stock	-	0.1	0.07	0.01	-	18.67
Other Financing Activities	-1.01	-0.9	-1.21	-0.74	-0.69	-1.7
Financing Cash Flow	2.53	3.28	-1.51	0.91	-0.19	17.68
Foreign Exchange Rate Adjustments	-0.04	-0.02	0.01	-0.29	-0.05	0.08
Net Cash Flow	-2.05	-2.44	-1.3	-1.76	-5.26	9.85
Free Cash Flow	-3.54	-4.93	0.63	-1.68	-4.53	-7.63
Free Cash Flow Margin	-12.77%	-17.22%	2.38%	-6.84%	-22.92%	-46.31%
Free Cash Flow Per Share	-0.05	-0.07	0.01	-0.02	-0.06	-0.17
Cash Interest Paid	1.01	0.9	0.85	0.74	0.69	0.55
Cash Income Tax Paid	-	-0.18	-0.27	-0.19	-0.62	-0.88
Levered Free Cash Flow	-5.41	-6.49	-0.19	-1.86	-3.65	-7.47
Unlevered Free Cash Flow	-4.79	-5.95	0.3	-1.43	-3.24	-7.19
Change in Working Capital	-1.48	-3.59	-0.24	-0.62	-0.47	-4.15

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.